Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRent ExpenseResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Cannabis Bioscience International Holdings (CBIH) Research & Development (2022 - 2026)

Cannabis Bioscience International Holdings' Research & Development history spans 5 years, with the latest figure at $983.0 for Q1 2026.

  • On a quarterly basis, Research & Development rose 357.21% to $983.0 in Q1 2026 year-over-year; TTM through Feb 2026 was $1321.0, a 106.41% increase, with the full-year FY2025 number at $517.0, down 74.96% from a year prior.
  • Research & Development hit $983.0 in Q1 2026 for Cannabis Bioscience International Holdings, up from $62.0 in the prior quarter.
  • Over the last five years, Research & Development for CBIH hit a ceiling of $1772.0 in Q1 2023 and a floor of $62.0 in Q4 2025.
  • Historically, Research & Development has averaged $661.64 across 5 years, with a median of $214.0 in 2025.
  • Biggest five-year swings in Research & Development: plummeted 91.65% in 2024 and later surged 357.21% in 2026.
  • Tracing CBIH's Research & Development over 5 years: stood at $1548.0 in 2022, then plummeted by 87.27% to $197.0 in 2023, then crashed by 50.76% to $97.0 in 2024, then crashed by 36.08% to $62.0 in 2025, then skyrocketed by 1485.48% to $983.0 in 2026.
  • Business Quant data shows Research & Development for CBIH at $983.0 in Q1 2026, $62.0 in Q4 2025, and $213.0 in Q3 2025.